Q3 EPS Estimates for NeoGenomics Boosted by Leerink Partnrs

NeoGenomics, Inc. (NASDAQ:NEO) – Research analysts at Leerink Partnrs boosted their Q3 2025 EPS estimates for NeoGenomics in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn $0.00 per share for the quarter, up from their previous estimate of ($0.01). The consensus estimate for NeoGenomics’ current full-year earnings is ($0.20) per share. Leerink Partnrs also issued estimates for NeoGenomics’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.04 EPS and FY2027 earnings at $0.28 EPS.

Other analysts have also recently issued reports about the stock. Needham & Company LLC decreased their price target on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday. The Goldman Sachs Group decreased their price target on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Jefferies Financial Group assumed coverage on shares of NeoGenomics in a research note on Tuesday, December 10th. They set a “buy” rating and a $22.00 price target on the stock. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Bank of America decreased their price target on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.80.

NeoGenomics Price Performance

Shares of NeoGenomics stock opened at $11.10 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -17.90 and a beta of 1.23. NeoGenomics has a 1-year low of $10.69 and a 1-year high of $19.11. The firm’s 50-day moving average price is $15.14 and its two-hundred day moving average price is $15.45.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%.

Hedge Funds Weigh In On NeoGenomics

Several large investors have recently bought and sold shares of NEO. Creative Planning lifted its holdings in NeoGenomics by 42.3% in the third quarter. Creative Planning now owns 23,547 shares of the medical research company’s stock valued at $347,000 after buying an additional 7,004 shares during the period. Blue Trust Inc. lifted its holdings in NeoGenomics by 42.3% in the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after buying an additional 987 shares during the period. Nisa Investment Advisors LLC raised its holdings in NeoGenomics by 5.0% in the third quarter. Nisa Investment Advisors LLC now owns 45,104 shares of the medical research company’s stock worth $665,000 after purchasing an additional 2,166 shares during the period. Fernwood Investment Management LLC raised its holdings in NeoGenomics by 1.0% in the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock worth $1,320,000 after purchasing an additional 900 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in NeoGenomics in the third quarter worth $1,101,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.